Number of the records: 1
Current and Future Pathways in Aspergillus Diagnosis
- 1.0571234 - MBÚ 2024 RIV CH eng J - Journal Article
Dobiáš, R. - Stevens, D. A. - Havlíček, Vladimír
Current and Future Pathways in Aspergillus Diagnosis.
Antibiotics (Basel). Roč. 12, č. 2 (2023), č. článku 385. ISSN 2079-6382. E-ISSN 2079-6382
R&D Projects: GA ČR(CZ) GA22-06771S
Institutional support: RVO:61388971
Keywords : aspergillosis * galactomannan * beta-D-glucan * pcr * metagenomic next-generation sequencing * lateral flow * bronchoalveolar lavage fluid * serum assays * siderophore * metallophore
OECD category: Microbiology
Impact factor: 4.8, year: 2022
Method of publishing: Open access
https://www.mdpi.com/2079-6382/12/2/385
Aspergillus fumigatus has been designated by the World Health Organization as a critical priority fungal pathogen. Some commercially available diagnostics for many forms of aspergillosis rely on fungal metabolites. These encompass intracellular molecules, cell wall components, and extracellular secretomes. This review summarizes the shortcomings of antibody tests compared to tests of fungal products in body fluids and highlights the application of beta-D-glucan, galactomannan, and pentraxin 3 in bronchoalveolar lavage fluids. We also discuss the detection of nucleic acids and next-generation sequencing, along with newer studies on Aspergillus metallophores.
Permanent Link: https://hdl.handle.net/11104/0342506
Number of the records: 1